Guyana is advancing plans to establish a National Pharmacovigilance Centre, a move intended to strengthen the country's oversight of medicines, vaccines and medical devices. The initiative has been supported by the Pan American Health Organization, working alongside the World Health Organization, and follows a workshop in Georgetown that brought together technical experts to guide the development of the new system. Officials describe the centre as a significant step in building a more robust regulatory structure for health products entering the country.

Pharmacovigilance refers to the science of monitoring the effects of medicines once they are in use, tracking adverse drug reactions and identifying safety signals that might not emerge during clinical trials. For a country the size of Guyana, building this capacity from scratch is no small undertaking. The plan forms part of a wider regulatory strengthening effort that began after Guyana adopted the PAHO Policy and Resolution on Regulatory System Strengthening in 2022. Since then, the Government Analyst–Food and Drug Department has carried out an assisted self-assessment using the WHO Global Benchmarking Tool, a process that helped identify gaps in the existing system. That work has fed into the drafting of a new Medicines Regulation Bill, which is expected to provide the legal underpinning for the reforms now under way.

The new centre is intended to do more than simply record adverse events. A central element of the plan is the introduction of VigiFlow, the global platform used for reporting adverse drug reactions, which would allow Guyana to feed information directly into international monitoring systems. The centre will also take on an expanded role as a post-market surveillance system, tasked with identifying substandard and falsified medical products once they have reached the market. This dual function is meant to give regulators a clearer picture of both safety concerns and quality failures across the supply chain. Guyana's participation in the WHO Programme for International Drug Monitoring is expected to deepen as a result.

Officials involved in the project have pointed to different aspects of its significance. Dr Kim Eva Dickson, PAHO's representative in Guyana, said a strong pharmacovigilance system allows safety concerns to be detected early and supports regulatory decisions built on evidence, adding that public confidence in medicines and vaccines depends on this kind of oversight. Tandeka Barton, acting director of the Government Analyst–Food and Drug Department, stressed that the system relies on contributions from healthcare workers, regulators and the public alike, describing every report as a step toward safer medicines. Frank Anthony, the Minister of Health, framed the changes as part of a broader push toward digital modernisation, telling those present that the government intends to use new tools across the health system and that medicines require monitoring throughout their entire life cycle rather than only at the point of approval.

The centre has not yet begun operating, and the timeline for its full establishment has not been set out publicly. What has been confirmed is the direction of travel: continued technical support from PAHO, further legislative work tied to the Medicines Regulation Bill, and a gradual build-out of the systems needed to make the centre functional. For a region where regulatory capacity varies considerably between countries, Guyana's progress will likely be watched by neighbouring health authorities considering similar reforms. PAHO has said it will continue supporting the Ministry of Health and the Government Analyst–Food and Drug Department as the work continues, though the practical results of the centre's work will only become clear once it is fully operational.